Biopharmaceutical company GC Biopharma announced on Monday that it has entered into an agreement with Novelty Nobility, a South Korea-based biotech company specialising in the development of antibody-based therapeutics.

The agreement covers the joint research and development of a novel treatment for geographic atrophy (GA).

According to the terms of the agreement, both companies are to jointly research and develop antibody-based protein therapeutics for GA throughout all stages of the drug development lifecycle. Under the first stage of the partnership, the two companies plan to strategically select novel proteins determined to play critical pathological roles in GA and identify therapeutic candidates accordingly.

Sang-gyu Park, Novelty Nobility chief executive officer, said, 'Novelty Nobility has been developing a next-generation treatment for wet AMD using a proprietary antibody for the past several years. We aim to leverage our in-house antibody drug development expertise in retinal disease to further expand into the GA treatment space. This collaboration with GC Biopharma will enable us to advance our research and potentially result in an innovative treatment that can be transformative for patients with GA.'